BeiGene, Mirati: Preliminary Data from Ongoing Trial Demonstrated Antitumor Activity
December 13 2019 - 8:44AM
Dow Jones News
By Michael Dabaie
BeiGene Ltd. (BGNE) and Mirati Therapeutics (MRTX) said
preliminary data from an ongoing Phase 1b trial of tislelizumab in
combination with sitravatinib in patients with platinum-resistant
ovarian cancer demonstrated antitumor activity and was generally
well tolerated.
"The initial results from this Phase 1b trial suggest further
development of this combination for the treatment of advanced solid
tumors, including platinum-resistant ovarian cancer, is warranted,"
Mirati Chief Executive Charles Baum said.
The Phase 1b trial of tislelizumab in combination with
sitravatinib consists of nine disease-specific cohorts in patients
with advanced solid tumors. The results were from cohort E in 20
patients with recurrent platinum-resistant ovarian cancer who
didn't have prior exposure to anti-PD-1/PD-L1 agents. At the data
cutoff, 17 patients were evaluable. Seven patients achieved a
partial response, including four confirmed PRs. The overall
response rate was 23.5% and eight patients achieved stable disease.
The median duration of response wasn't reached.
The median progression-free response was 18 weeks and the PFS
rate at 3 months and 6 months was 88.2% and 35.3% respectively.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 13, 2019 08:29 ET (13:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From May 2023 to May 2024